Abstract
N-(4-Hydroxyphenyl)retinamide (4HPR) is currently used in cancer prevention and therapy trials. It is thought that its effects result from induction of apoptosis. 4HPR-induced apoptosis in human cervical carcinoma C33A cells involves enhanced generation of reactive oxygen species (ROS). In this study we explored the mechanism by which 4HPR increases ROS and induces apoptosis in these cells. 4HPR induced cytochrome c release from mitochondria to cytoplasm, activated caspase-3, and caused a membrane permeability transition (MPT). All these 4HPR's effects, as well as the induction of apoptosis, were inhibited by antioxidants, which decrease ROS. Thenoyltrifluoroacetone, a mitochondrial respiratory chain (MRC) complex II inhibitor, and carbonylcyanide m-chlorophenyl hydrazone, which uncouples electron transfer and ATP synthesis and inhibits ROS generation by MRC, inhibited 4HPR-induced ROS generation very effectively. Rotenone, an MRC complex I inhibitor was less effective and azide, an MRC complex IV inhibitor, exhibited a marginal effect. In contrast, antimycin A, an MRC complex III inhibitor, enhanced 4HPR-induced ROS generation. These findings suggest that 4HPR enhances ROS generation by affecting a target between complex II and complex III, presumably coenzyme Q. This effect is followed by release of cytochrome c, increased caspase-3 activity, induction of MPT and eventual DNA fragmentation and cell death.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Berridge MV and Tan AS. . 1993 Arch. Biochem. Biophys. 303: 474–482.
Beyer RE. . 1992 Biochem. Cell Biol. 70: 390–403.
Bezkorovainy A and Rafelson Jr ME. (eds). . 1996 Metabolism and oxidative phosphorylation. Marcel Dekker, Inc., New York, NY.
Bossy-Wetzel E, Newmeyer DD and Green DR. . 1998 EMBO J. 17: 37–49.
Caraceni P, Ryu HS, Thiel DH and Borle AB. . 1995 Biochim. Biophys. Acta 1268: 249–254.
Dawson TL, Gores GJ, Nieminen AL, Herman B and Lemasters JJ. . 1993 Am J Physiol. 264: C961–C967.
Delia D, Aiello A, Meroni L, Nicolini M, Reed JC and Pierotti MA. . 1997 Carcinogenesis 18: 943–948.
Fedyk ER and Phipps RP. . 1994 Int. J. Immunopharmacol. 16: 533–546.
Forman HJ and Boveris A. . 1982 In: Free Radicals in Biology, Vol. V. Pryor WA. (ed.).. Academic Press: New York, NY pp. 65–90.
Formelli F, Barua AB and Olson JA. . 1996 FASEB J. 10: 1014–1024.
Garcia-Ruiz C, Colell A, Mari M, Morales A and Fernandez-Checa JC. . 1997 J. Biol. Chem. 272: 11369–11377.
Goodman Y, Steiner MR, Steiner SM and Mattson MP. . 1994 Brain Res. 654: 171–176.
Gorman A, McGowan A and Cotter TG. . 1997 FEBS Lett. 404: 27–33.
Green DR and Reed JC. . 1998 Science 281: 1309–1312.
Henderson LM, Chappell JB and Jones OT. . 1989 Biochem J. 264: 249–255.
Higuchi M, Aggarwal BB and Yeh ET. . 1997 J. Clin. Invest. 99: 1751–1758.
Higuchi, M, Honda T, Proske RJ and Yeh ET. . 1998 Oncogene 17: 2515–2524.
Higuchi M, Singh S, Jaffrezou JP and Aggarwal BB. . 1996 J. Immunol. 157: 297–304.
Hu H, Sosnovsky G and Swartz HM. . 1992 Biochim. Biophys. Acta 1112: 161–166.
Hunt NH and Fragonas JC. . 1992 Biochim. Biophys. Acta 1133: 261–267.
Jacobson MD, Weil M and Raff MC. . 1996 J. Cell. Biol. 133: 1041–1051.
Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD. . 1997 Science 275: 1132–1136.
Kruidering M, Van de Water B, de Heer E, Mulder GJ and Nagelkerke JF. . 1997 J. Pharmacol. Exp. Ther. 280: 638–649.
Lennon SV, Martin SJ and Cotter TG. . 1991 Cell Prolif. 24: 203–214.
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X. . 1997 Cell 91: 479–489.
Liu X, Kim CN, Yang J, Jemmerson R and Wang X. . 1996 Cell 86: 147–157.
Lotan R. . 1995 J. Natl. Cancer Inst. 87: 1655–1657.
Marchetti P, Castedo M, Susin SA, Zamzami N, Hirsch T, Macho A, Haeffner A, Hirsch F, Geuskens M and Kroemer G. . 1996a J. Exp. Med. 184: 1155–1160.
Marchetti P, Susin SA, Decaudin D, Gamen S, Castedo M, Hirsch T, Zamzami N, Naval J, Senik A and Kroemer G. . 1996b Cancer Res. 56: 2033–2038.
Martin SJ, Newmeyer DD, Mathias S, Farschon DM, Wang HG, Reed JC, Kolesnick RN and Green DR. . 1995 EMBO J. 14: 5191–5200.
McCord JM. . 1985 N. Eng. J. Med. 312: 159–163.
Meyer M, Schreck R and Baeuerle PA. . 1993 EMBO J. 12: 2005–2015.
Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA et al. 1995 Nature 376: 37–43.
Nohl H. . 1987 FEBS Lett. 214: 269–273.
Nohl H and Jordan W. . 1986 Biochem. Biophys. Res. Commun. 138: 533–539.
O'Donnell VB, Spycher S and Azzi A. . 1995 Biochem. J. 310: 133–141.
Oishi K and Machida K. . 1997 Scand. J. Immunol. 45: 21–27.
Oridate N, Lotan D, Mitchell M, Hong WK and Lotan R. . 1995 Int. J. Oncol. 7: 433–441.
Oridate N, Lotan D, Xu XC, Hong WK and Lotan R. . 1996 Clin. Cancer Res. 2: 855–863.
Oridate N, Suzuki S, Higuchi M, Mitchell MF, Hong WK and Lotan R. . 1997 J. Natl. Cancer Inst. 89: 1191–1198.
Ormerod MG, Sun XM, Brown D, Snowden RT and Cohen GM. . 1993 Acta Oncol. 32: 417–424.
Richter C and Schweizer M. . 1997 In: Oxidative stress and the molecular biology of antioxidant defenses. Scandalios JG. (ed.).. Cold Spring Harbor Laboratory Press: Plainview, NY pp. 169–200.
Sanford KK, Parshad R, Price FM, Tarone RE and Kraemer KH. . 1992 J. Clin. Invest. 90: 2069–2074.
Schlegel J, Peters I, Orrenius S, Miller DK, Thornberry NA, Yamin TT and Nicholson DW. . 1996 J. Biol. Chem. 271: 1841–1844.
Schulze-Osthoff K, Bakker AC, Vanhaesebroeck B, Beyaert R, Jacob WA and Fiers W. . 1992 J. Biol. Chem. 267: 5317–5323.
Schulze-Osthoff K, Beyaert R, Vandevoorde V, Haegeman G and Fiers W. . 1993 EMBO J. 12: 3095–3104.
Shimizu S, Eguchi Y, Kamiike W, Funahashi Y, Mignon A, Lacronique V, Matsuda H and Tsujimoto Y. . 1998 Proc. Natl. Acad. Sci. USA 95: 1455–1459.
Shimizu S, Eguchi Y, Kamiike W, Itoh Y, Hasegawa J, Yamabe K, Otsuki Y, Matsuda H and Tsujimoto Y. . 1996 Cancer Res. 56: 2161–2166.
Skulachev VP. . 1996 Quart. Rev. Biophys. 29: 169–202.
Sun S-Y, Li W, Yue P, Lippman SM, Hong WK, and Lotan R. . (1999). Cancer Res., in press.
Taylor DE, Ghio AJ and Piantadosi CA. . 1995 Arch. Biochem. Biophys. 316: 70–76.
Trudel S, Paquet MR and Grinstein S. . 1991 Biochem J. 276: 611–619.
Turrens JF, Alexandre A and Lehninger AL. . 1985 Arch. Biochem. Biophys. 237: 408–414.
Wolvetang EJ, Johnson KL, Krauer K, Ralph SJ and Linnane AW. . 1994 FEBS Lett. 339: 40–44.
Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP and Wang X. . 1997 Science 275: 1129–1132.
Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssiere JL, Petit PX and Kroemer G. . 1995 J. Exp. Med. 181: 1661–1672.
Zamzami N, Susin SA, Marchetti P, Hirsch T, Gomez-Monterrey I, Castedo M and Guido K. . 1996 J. Exp. Med. 183: 1533–1544.
Zoratti M and Szabo I. . 1995 Biochim. Biophys. Acta 1241: 139–176.
Zou CP, Kurie JM, Lotan D, Zou CC, Hong WK and Lotan R. . 1998 Clin. Cancer. Res. 4: 1345–1355.
Acknowledgements
This study was supported in part by United States Public Health Service Grant PO1 CA52051 from the National Cancer Institute. We thank Dafna Lotan for her excellent technical assistance. WK Hong is a Clinical Research Professor for the American Cancer Society. R Lotan is an incumbent of the Irving and Nadine Mansfield and Robert David Levitt Cancer Research Chair.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Suzuki, S., Higuchi, M., Proske, R. et al. Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-Hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. Oncogene 18, 6380–6387 (1999). https://doi.org/10.1038/sj.onc.1203024
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203024
Keywords
This article is cited by
-
Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies
Cancer Chemotherapy and Pharmacology (2023)
-
A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors
Cancer Chemotherapy and Pharmacology (2021)
-
Loss of MKP-5 promotes myofiber survival by activating STAT3/Bcl-2 signaling during regenerative myogenesis
Skeletal Muscle (2017)
-
Redox cycling of Cu(II) by 6-mercaptopurine leads to ROS generation and DNA breakage: possible mechanism of anticancer activity
Tumor Biology (2015)
-
Toxicity of Copper on Isolated Liver Mitochondria: Impairment at Complexes I, II, and IV Leads to Increased ROS Production
Cell Biochemistry and Biophysics (2014)